The (increased) impact of technology on IP: How will it affect YOUR career?! Who can attend: Young Practitioners and Trademark Administrators from the Nordic and Baltic countries with no more than five years of professional experience. INTA membership is not required to participate. Co-hosting firms: BAHR (Oslo, Norway), BRIMONDO (Göteborg, Sweden), CASTRÉN & SNELLMAN (Helsinki, Finland), DARTS-IP (Brussels, Belgium), LUNDGRENS […] Read More
The Stockholm Intellectual Property Law Review (SIPLR) welcomes submissions for its two next issues. Authors are invited to submit original research papers, essays and book reviews on either General Topics of European and International IP Law, and on Food, the latter resulting in SIPLR’s second thematic issue. SIPLR is a student-led review first published in January 2018. Two issues covered […] Read More
Editorial Preface “Some industries are different but some are more different than others. The pharmaceutical industry fits the latter category” (Scherer 1996:336). There is really no other industry where the nature of the products, the economics of research and development as well as the market structure and the societal implications of the industry’s strategic decisions are as unique as in […] Read More
The tragic 9/11 events in 2001 implied a delay in the court proceedings in Boston that dealt with a case involving AstraZeneca and its blockbuster drug Losec (Prilosec in the US). The key basic patent for this drug had been received by the Swedish company Astra in the US in 1981 (US patent # 4.255.431, issued March 10, 1981). Astra […] Read More
ABSTRACT The CRISPR/Cas9 discovery has emerged as a powerful technology tool to edit genomes, which allows researchers, innovators and life science entrepreneurs to alter DNA sequences and modify gene function in a range of species. The simplicity, high efficiency and seemingly broad use of the CRISPR/Cas9 system has led to hopes that this disruptive technology may have the potential to […] Read More
Has Lord Neuberger in Actavis introduced “an amorphous general inventive idea” test to determine UK patent infringement by equivalents? Are “inessential integers”, once found extremely rarely , now to be embraced as part of normal UK practice? Have UK patent claims become “a puzzle game”? Read this article as a PDF
ABSTRACT Second medical use patents and their claims do not only represent highly valuable inventions for both originator and generic pharmaceutical companies, but have also been a topic of debate for many years. In particular, this is due to the fact that these inventions were originally not patentable under the European Patent Convention (EPC) in 1973 and thus required a […] Read More